Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Why GSK and Sanofi Shares are Trading Sharply Lower This Week

Published 11/08/2022, 13:58
Updated 11/08/2022, 13:58
© Reuters.

© Reuters.

By Senad Karaahmetovic

Shares of GSK (NYSE:GSK), formerly GlaxoSmithKline, are down over 8% in premarket Thursday amid mounting concerns about the recalled drug Zantac.

The company is facing lawsuits as it allegedly failed to warn users about the over-the-counter product’s health risks. Zantac was a popular drug that was recalled since it allegedly causes cancer.

Sanofi (EPA:SASY) shares are also down, as much as 9% in European trading today as investors closely watch developments surrounding Zantac litigations. GSK, Sanofi, and Haleon (NYSE:HLN) have lost $40 billion in combined market valuation since Tuesday.

Investors will be focused on an upcoming Illinois case on August 22, as well as some other key court trials that are scheduled for early 2023. Analysts note that the key trial will start in mid-2023.

A Deutsche Bank analyst sees near-term headwinds for both Sanofi and GSK.

“This topic is not new: it has arrived in investor consciousness in recent days it seems, but been rumbling on in the background for a few years. What is true is that it is approaching visibility in the form of first cases. We don’t think the evidence points to this as another glyphosate, but it is very possible we may see a liability of some $bn magnitude incurred which, coupled with negative headlines from the slate of imminently pending cases,” the analyst told clients in a note.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.